Navigation Links
Age alone should not be used to determine whether to treat prostate cancer with hormones
Date:9/24/2008

BOSTON -- Concerns regarding the association of hormone therapy used to treat prostate cancer with cardiovascular disease in some older men may lead doctors to forgo hormone treatment solely on the basis of age. But a new study by physicians at Fox Chase Cancer Center shows that men over age 70 with high-risk prostate cancer lived longer and experienced increases in PSA less frequently when treated with long-term androgen deprivation therapy.

The benefit of long-term (i.e. 2-3 years) androgen deprivation therapy has been established in high-risk prostate cancer patients in several prospective, randomized clinical trials. However, concern that androgen deprivation therapy may result in cardiovascular disease, particularly in older patients men with certain risk factors for cardiovascular disease, has led investigators to question its role in older men.

"Several studies have demonstrated a survival benefit when androgen deprivation therapy is used along with radiotherapy in men with high-risk, clinically localized prostate cancer," said the study's lead author, Joshua Silverman, MD, PhD, a resident in the Department of Radiation Oncology at Fox Chase. "What we did not know until now is whether this benefit outweighs the risks of cardiovascular and metabolic adverse effects from androgen deprivation therapy."

In this retrospective study presented today at the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology, researchers identified men with prostate cancer that was confined to the prostate, but considered high-risk (i.e. pre-treatment PSA ≥ 20, Gleason score 8-10, or larger tumors palpable during digital rectal exam) and looked at outcomes with and without the use of hormone therapy.

"We know the risk of distant metastasis, recurrence and death are higher when androgen deprivation therapy is not part of radiation treatment," said Silverman. "We wanted to see if age should be a determining factor for treatment with hormone suppression."

Researchers found the overall rate of biochemical failure (i.e., a rise in the PSA level) is lower for men who received hormone therapy regardless of age. A rise in PSA can indicate the recurrence or spread of prostate cancer and often leads to more testing and more aggressive treatments.

"We saw the greatest advantage of hormone therapy among men who received a longer duration of androgen deprivation therapy, including those with pre-existing cardiovascular and metabolic concerns," said Silverman.

A longer duration (more than 12 months) of hormone therapy resulted in a greater overall survival for all men (≤12 months-87 percent, ≥ 12 months-98 percent; p=0.02) including in men older than 70 (≤12 months-80 percent, ≥ 12 months-98 percent; p=0.03).

Men under 70 who received hormone therapy had a greater 5 year overall survival rate (96 percent v 91 percent; p0.03) than did men over 70 (89 percent v. 86 percent; 0.17).

"This may be explained in part by a trend toward greater pre-existing cardiovascular concerns in men over age 70," Silverman said.

Still, Silverman said, "We concluded that age alone should not be considered a contraindication to hormone treatment in high-risk patients. While co-morbidities may influence clinical decision-making regarding androgen deprivation therapy, we do not have enough data to select patients who should or should not receive treatment of a shorter duration based on age alone."

"One weakness of this study is selection bias because men in this retrospective analysis were not randomized to androgen deprivation therapy." Silverman said, "We still need to continue our careful consideration of each individual's health before recommending androgen deprivation therapy."

Silverman added that the study does not address the impact hormones may have on a man's quality of life. The adverse effects of hormones include muscle loss, cognitive issues, loss of libido, and osteoporosis.


'/>"/>

Contact: Karen Mallet
karen.mallet@fccc.edu
414-312-7085
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Is Mom or Dad Safe to Live Alone?
2. Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of Nearly $5 Billion in the First Nine Months of 2007
3. Enlarged Prostate Treatment Study Shows Combination of AVODART(R) and Tamsulosin Provides Greater Benefit Than Either Medication Alone
4. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
5. Youre Not Alone: How Mothers of Children Born with Rare Condition Comfort and Support Each Other on CarePages.com
6. Houston-Based LifeGift Becomes States Only Stand-Alone Organ and Tissue Recovery Agency
7. Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults
8. Drugs Alone Dont Lower Heart Disease Risks for Overweight Americans
9. Parents Worry About Tweens Left Alone
10. Pregnancy Alone Not A Risk for Mental Health Problems
11. Medifast Program Combined with Appetite Suppressants Proven to Yield Double the Weight Loss Compared to Suppressants Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Steve Helwig ... with a vital new community enrichment program, has teamed up with Citizens Opposed to ... children suffering from intimate abuse. To support all those victimized by the fear of ...
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 8. Februar 2016  LivaNova, PLC, Hersteller ... Infografik mit dem Titel „Epilepsy Around the ... der der Krankheit gegenüber ein größeres Bewusstsein ... soll, Medikamentenresistenz bei Epilepsie auf dem Internationalen ... zu machen. Mithilfe der neuen Infografik sollen ...
(Date:2/5/2016)... Va. , Feb. 5, 2016  ivWatch, a medical ... Virginia Outstanding STEM Award granted by Governor Terry McAuliffe,s ... Science Innovation on February 25th at an event to be ... . The STEM award honors professionals and business that have ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at Source Capital Group,s 2016 Disruptive Growth & ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  Mr. ... place at 3:15 p.m. ET. http://www.aethlonmedical.com .  The ... the conclusion of the live event. The panel discussion will ...
Breaking Medicine Technology: